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1. Introduction 
This chapter will examine pharmacological approaches to neuromodulation in Autism 
Spectrum Disorders (ASD), pharmacological clinical trials and pharmacological strategies 
on the horizon. 
Drugs used in autism target neuromodulation at different neuronal sites. Those utilizing anti-
convulsant, neurolepic, anti-depressant, stimulant, cholinesterase inhibitors, anxiolytics, mood 
stabilizers and other pharmacological interventions in autism do so for a variety of purposes. 
Each of these classes of drugs will be examined relative to their proposed neuromodulatory 
actions as they relate to the Autism Spectrum Disorder population. 
Children with ASD demonstrate deficits in 1) social interaction, 2) verbal and nonverbal 
communication, and 3) repetitive behaviors or interests. Many have unusual sensory 
responses. Symptoms range from mild to severe and present with individual uniqueness 
and complexity. Some aspects of learning may seem exceptional while others may lag. These 
children reflect a mix of communication, social, and behavioral patterns that are individual 
but fit into the overall diagnosis of ASD. Aggression, irritability and/or self-injury in 
children with autistic spectrum disorders often meet the threshold indicating 
pharmacological intervention.  
Autism Spectrum Disorders have been shown to be related to complex combinations of 
environmental, neurological, immunological, and genetic factors. In addition to strong 
genetic links, environmental factors such as infection and drug exposure during pregnancy, 
perinatal hypoxia, postnatal infections and metabolic disorders have each been implicated in 
autistic populations. Summarizing an earlier Centers for Disease Control and Prevention 
Study (CDC)  with subsequent major studies on autism prevalence, the CDC estimates 2-6 
per 1,000 (from 1 in 500 to 1 in 150) children have an ASD. The risk is 3-4 times higher in 
males than females (Rice 2006)(CDC 2011). 
The pathogenetic components and biological endophenotypes in autism spectrum disorders 
were described by Sacco and colleagues as: Circadian & Sensory Dysfunction; Immune 
Dysfunction; Neurodevelopmental Delay; and Stereotypic Behavior (Sacco R, et al 2010). 
The heterogeneity of Autism Spectrum Disorders has resulted in many genes being studied 
that are thought to have an impact on the development of the pathological characteristics 
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associated with Autism Spectrum Disorder (Greer PL, et al 2010). The developmental 
neurobiology of ASD is incrementally illuminated at the cutting edges of science. The 
permutations of mutations and epigenetic effects in ASD are both daunting yet increasingly 
identifiable targets for pharmacologic intervention. Clinical necessity and clincial trials drive 
discoveries for therapeutic interventions until stem cell or genetic solutions arrive.  
Some states or effects seen in ASD may be responsive to developmental interventions while 
others may not. As we know, prompt thyroid replacement in a hypothyroid infant will 
generally allow normative intellectual development and prevent developmental disability. 
An example of variation of developmental impact is a mutation in MECP2, which encodes 
the epigenetic regulator methyl-CpG-binding protein 2 and is associated with Rett 
Syndrome. A recent study asked the question whether providing MeCP2 function 
exclusively during early post-natal life might prevent or mitigate disease in adult animals. 
Re-expression of MeCP2 in symptomatic mice rescued several features of the disease. The 
investigators argue “…the temporal association of disease with the postnatal period of 
development may be unrelated to any 'developmental' or stage restricted function of 
MeCP2, at least in mouse models.” They concluded that “…therapies for RTT, like MeCP2 
function must be continuously maintained” (McGraw, et al 2011). 
Genetic-environment interactions in ASD that continue to be investigated include:  parental 
age; maternal genotype; maternal-fetal immunoreactivity; in vitro fertilization; maternal 
ingestion of drugs; toxic chemicals in the environment during pregnancy; and maternal 
illnesses during pregnancy such as maternal diabetes or infections (Hallmayer J, 2011) . 
Recent studies are consistent with a fetal programming hypothesis of ASD that considers 
environmental risk factors that affect the fetal environment and interact with genetic 
variants (Szatmari 2011). The pathogenic potential of dysregulated states may further stress 
developmentally vulnerable neurodevelopment (Duke, B. , 2008).  
As these genes and interacting effects become better characterized therapeutic strategies can 
be developed (Buxbaum 2009) (Levy et al, 2011)(Sanders et al, 2011)(Gilman et al, 2011). 
These genes include those involved in the patterning of the central nervous system; those 
that govern biochemical pathways; those responsible for the development of dendrites and 
synapses; and, genes associated with the immune system and autoimmune disorders 
(Ashwood et al, 2006 ) (Careaga M et al,  2010 ). 
Neuroimaging studies further enlighten our theoretical models and techniques such as 
diffusion tensor imaging (DTI) have gained prominence as a means of assessing brain 
development (Isaacson & Provenzale,  2011). Studies of emotional perception demonstrated 
that while listening to either happy or sad music, individuals with ASD activated cortical 
and subcortical brain regions known to be involved in emotion processing and reward. The 
investigators, using functional magnetic resonance imaging compared ASD participants 
with neurotypical individuals and found ASD individuals had decreased brain activity in 
the premotor area and in the left anterior insula, especially in response to happy music 
excerpts. Their findings illuminate our understanding of the neurobiological correlates of 
preserved and altered emotional processing in ASD (Caria A, et al  2011).  
Other imaging studies have found: diminished gray matter within the hypothalamus in 
autism disorder and suggest this is a potential link to hormonal effects (Kurth F, et al 2011); 
elevated repetitive and stereotyped behavior (RSB) associated with decreased volumes in 
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several brain regions: left thalamus, right globus pallidus, left and right putamen, right 
striatum and a trend for left globus pallidus and left striatum within the ASD group (Estes 
A, et al 2011 ); alterations in frontal lobe tracts and corpus callosum in young children with 
autism spectrum disorder (Kumar A, et al  2010); and, revealed pervasive microstructural 
abnormalities (Groen WB, et al 2011).  
As our theoretical constructs are tested and enriched clinical scientists are poised to learn 
exponentially as treatment response databases and measurement methods and systems are 
further developed. We are ready to experience an evolution and fusion of medical arts 
strengthened by scientific methods and information technology.  
Psychopharmacological treatment guidelines for very young children suggest that children 
with persistent moderate to severe symptoms and impairment, despite psychotherapeutic 
interventions, may be better served by carefully monitored medication trials than by 
continuing ineffective treatments (Gleason MM, et al 2007).  
The treatment of children with ASD has challenges that are also present in the treatment  
of many mood disorders and in schizophrenia. In Stephen Stahl’s text, Essential 
Psychopharmacology (Stahl 2010), he deconstructs the syndrome of schizophrenia into five 
symptom dimensions: Positive and Negative symptoms, aggression, affect and cognition. 
These symptom dimensions are also relevant to children with ASD and many children with 
mood disorders. Individual presentations and variability of treatment response can be 
managed by enlisting the parents to be observers utilizing defined measurements.  
Multiple medications have utility in ASD treatment and are sometimes used in combination. 
Thoughtful utilization and management of medications can offer children with autism 
spectrum disorders significiant reductions of impairment. Each of the medications used, as 
true with any medication, has varying degrees and potential related to benefits, risk and 
limitations. Although the antipsychotic risperidone has been demonstrated as effective in 
reducing serious behavioral problems, it shares adverse neurological and metabolic risks 
with other typical and atypical antipsychotic agents. Nevertheless, risperidone has 
demonstrated efficacy at relatively low doses and treatment monitoring can assist in 
managing risks when substantial benefit is possible.  
Antidepressants have been reported as helpful for some with ASD, particularly related to 
repetitive or obsessive compulsive behaviors, however, studies reviewing off-label uses of 
anti-depressants have also reported adverse effects of increased agitation, behavioral 
activation and sleep disturbance. If we consider these findings as evidence suggesting 
antidepressants, in some, perturb inhibitory- excitatory neuronal balance or, in a broad sense, 
contribute to central nervous system hyperarousal, it follows that such effects could contribute 
to pathogenesis rather than decrease the allostatic load. This does not suggest that anti-
depressant medications can’t be helpful. It is recognized that in many cases antidepressants are 
helpful; however, vigilance for signs of disinhibition or other dysregulation is prudent.  
Known stimulant benefits include increased ability to sustain attention, reduced motoric 
hyperactivity and reduced impulsivity. Adverse effects associated with stimulants include 
dysphoric responses, sleep disturbances and appetite supression.  
Anticonvulsants have demonstrated their place in the treatment regimen of many children 
with ASD and approximately twenty percent of those with ASD are thought to have a 
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seizure disorder (Tuchman & Cuccaro, 2011). Benefits can include seizure control and mood 
stabilization while adverse effects can include cognitive dulling. When anticonvulsants are 
useful, cognitive dulling can often be managed by anticonvulsant selection and dosing.  
Current pharmacological interventions in autism spectrum disorders are essentially directed 
at reducing cognitive and behavioral impairments. Treatment studies have demonstrated 
little observable benefit to core deficits of ASD, however, the argument is made that, in 
addition to the practical benefits of reducing behavioral and cognitive impairments, 
symptom reduction is a reflection of more efficient neural processing and development.  
Effective impairment reduction often allows children to remain in a family home, function 
in a school setting, optimize reponsiveness to behavioral and educational methods and, 
generally,  function more normally than would otherwise be possible. Those of us who treat 
children who will otherwise be excluded from normal environments appreciate the 
importance and complexity of these interventions. The greater promise of pharmacological 
interventions is their potential, through early intervention, to inhibit or reduce the 
development of pathological and pathogenic endophenotypes.  
2. Conceptualization of clinical hypotheses, treatment strategies and 
measurement of treatment response 
Physicians and clinician- scientists are humbled distinguishing among nosological 
categories in the context of the diverse and complex treatment circumstances presented by 
those significantly impaired within the spectrum of autism disorders.  
Treatment decisions are based on symptom profiles, types and severity of impairment, risk-
benefit calculations, potential treatments available and clinical hypotheses related to the 
nature of the disorder. Unlike elegantly designed experiments with exquisitely defined 
variables and thoughtful control of confounding variables, those suffering functional and 
qualitative impairment present with inherent experimental limitations. Despite these 
limitations, the application of scientific principles related to individual measurement and 
monitoring of treatment response provides a platform from which to assess treatment 
response and dynamically test clinical hypotheses.   
The deconstruction of psychiatric syndromes into symptoms is described as a way to 
establish a diagnosis, deconstruct the condition into its symptoms, match the symptoms to a 
hypothetically malfunctioning circuit and consider the collection of neurotransmitters and 
neuromodulators known to regulate the circuit. "Next, one can match each symptom to a 
hypothetically malfunctioning circuit and – with knowledge of the neurotransmitters 
regulating that circuit and drugs acting on those neurotransmitters – choose a therapeutic 
agent to reduce that symptom. If such a strategy proves unsuccessful, it is possible that 
adding or switching to another agent acting on another neurotransmitter in that circuit can 
be effective. Repeating this strategy for each symptom can result in remission of all 
symptoms in many patients.” (Stahl, 2010) 
Knowledge gained in the study of abnormal circuitry in mood disorders, schizophrenia and 
other neuropsychiatric and neurological conditions provide models by which treatment 
responses and clinical hypotheses can be tested. Whether the symptoms are hyperkinetic 
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movement disorders or hyperactive mesolimbic systems, pharmacological strategies can 
inform and interact with the rapidly developing basic and translational sciences. 
Dysregulation of neuronal inhibition and excitability appears as a common theme among 
many disorders. 
Consideration of the pathological developmental aspects of autism spectrum disorders 
provokes the possibility that altering disease progression may rescue or support improved 
functional neurodevelopmental outcomes. In a broad statement regarding psychiatric 
disorders that supports that potential, Stephen Stahl remarks, “It may also be possible to 
prevent disease recurrence and progression to treatment resistance by treating not only 
symptoms but also inefficient brain circuits that are asymptomatic. Failing to do so may 
allow ‘diabolical learning’ where circuits run amok, become more efficient in learning how 
to mediate symptoms, and are therefore more difficult to treat." (Stahl, 2010, p. 274) 
The lessons and theoretical models related to pharmacological interventions in other 
neurological and psychiatric syndromes can be applied to treatment conceptualizations with 
the autistic spectrum disordered as well. For example, constructs investigated with 
antiepileptic drugs (AED) can also be considered within the neural circuitry issues involved 
in Autism Spectrum Disorders. 
“Several pathophysiological mechanisms inducing a neuronal excitability seems to be 
involved in an imbalance of both GABAergic and glutamatergic neurotransmissions and 
therefore could be similar in epilepsy and hyperkinetic movement disorders. The main 
targets for the action of the AEDs include enhancement of GABAergic inhibition, decreased 
glutamatergic excitation, modulation of voltage-gated sodium and calcium channels, and 
effects on intracellular signaling pathways. All of these mechanisms are of importance in 
controlling neuronal excitability in different ways.” (Siniscalchi, Gallelli & De Sarro, 2010) 
When pharmacological interventions are applied, secondary to their clinical intent, they 
serve as probes of endophenotypic neural functioning and circuitry states revealing 
response to particular pharmacodynamic and pharmacokinetic profiles. The classes of 
antipsychotic drugs considered to be atypical are described by Schwartz with such 
considerations in mind.  
"The second generation antipsychotics are clearly delineated in the treatment of psychosis 
and mania and share similar mechanisms of action to achieve these results: dopamine-2 
receptor antagonism for efficacy and serotonin-2a receptor antagonism for EPS tolerability. 
From here, each agent has a unique pharmacodynamic and pharmacokinetic profile where 
some agents carry more, or less antidepressant, anxiolytic, or hypnotic profiles. Choosing an 
agent and dosing it in low, middle, or high ranges may result in differential effectiveness 
and tolerability" (Schwartz & Stahl, 2011 ). 
We are further humbled by the incomplete pharmacodynamic and pharmacokinetic 
profiles of the drugs we employ. Many of the drugs and compounds used have poorly 
understood neuromodulary effects in addition to known receptor specific actions. 
Nevertheless, contributions to our knowledge continue to further characterize and define 
drugs as well as continue to discover relationships of enviromental effects and 
immunological response. Researchers, for example, have recently shown the inhibitory 
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effects of some antidepressants as well as some typical/atypical antipsychotics on the 
release of inflammatory cytokines and free radicals from activated microglia, which the 
investigators state have been discovered to cause synaptic pathology, a decrease in 
neurogenesis, and white matter abnormalities found in the brains of patients with 
psychiatric disorders. (Monji A, 2011). We operate with limited visibility that is increased 
by clinical experience and science. 
Despite the complexity and challenges of ASD, potential for early interventions are 
supported by animal research. An example is the recent demonstration that autism risk 
genes differentially impact cortical development (Eagleson K, et al  2011). The 
demonstrations of these risk genes and their interaction with various states, illustrate animal 
models that may further elucidate pathogenic developmental processes. The role of 
glutamate (Hamberger A, et al  1992 ), serotonin (Levitt P, 2011) and sigma 1 ligands 
(Yagasaki Y, et al  2006) have each demonstrated potential importance in modulating 
glutamatergic and other developmentally critical signaling processes.  
In autism spectrum disorders as well as in other neurological and neurodegenerative 
disorders, discoveries in developmental neurobiology and genetics will continue to provide 
increasingly sophisticated models in which interventions of developmentally specific 
neuropathogenic processes can be assessed and clinical hypotheses considered and tested. 
Coinciding are increasingly sophisticated objective measures that will allow greater 
definition of treatment response characteristics and endophenotypic response profiles. 
Applications related to treatment response measurement and management utilizing on-line 
observational and other measurements related to eye, facial, voice, reaction time 
consistency, sleep and activity are currently being studied and developed at the Child 
Psychopharmacolgy Institute.   
3. Registered clinical trials (NIH- USA) in autism spectrum disorders 
We can learn a great deal from the current foci of pharmacological interventions in ASD by 
reviewing clinical trials that have been conducted and those that are current. 
 
 Frequency Percent 
Drug Studies 151 53.5
Behavioral Studies 43 15.2
Dietary Studies 18 6.4
Device or Procedure Studies 5 1.8
Obervational and Other Studies 65 23.0
Total 282 100.0
 
Table 1. ASD Study Types- NIH Registrations of Record July 2011 
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Drug Classes Used In Autism Spectrum Disorder Clinical Trials 
Antidepressant
Stimulant
Anticonvulsant
Antipsychotic
NMDA Antagonists And Glutamatergic
Antibacterial Anti-Infective
Immunomodulator
Hyperbaric Oxygen
Hormone Or Enzyme Factors
Adrenergic
Anti-Hypertensive
Diruretic
Opioid Antagonist
Anti-Oxidants
Hypoglycemic Agents
Supplements
GABA B Recepter Agonist
Trichuris Suis Ova
Antidote Heavy Metal
Ampa Receptor Modulator
Anxioytic
Table 2. Drug Classes Used in Autism Spectrum Disorder July 2011 NIH 
 
Fig. 1. Spectrum of Drug Classes in Autism Spectrum Disorders  
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Fig. 2. NLM Clinical Trial Reviews 2006 to 2011 
Table 3 displays a sampling of drugs in clinical trials and their generally proposed actions. 
 
Antipsychotic Drugs
Risperidone is a selective blocker of dopamine d2 receptors and serotonin 5-ht2 receptors 
that acts as an atypical antipsychotic agent.
Aripiprazole has both presynaptic dopamine autoreceptor agonistic activity and 
postsynaptic D2 receptor antagonistic activity; use associated with hyperglycemia. It can 
also be described as a Dopamine Partial Agonist.
Ziprasidone -antipsychotic-A benzisothiazoylpiperazine derivative; has combined 
dopamine and serotonin receptor antagonist activity; structurally related to tiospirone. 
Zyprexa (olanzapine)  has combined dopamine and serotonin receptor antagonist activity. 
Antidepressant Drugs
Fluoxetine:  serotonin specific uptake inhibitor
Citalopram serotonin specific uptake inhibitor. The drug is also effective in reducing 
ethanol uptake in alcoholics and is used in depressed patients who also suffer from tardive 
dyskinesia 
The SSRI fluvoxamine is not only an inhibitor of SERT, but also acts at sigma receptors, 
perhaps as a sigma-1 agonist, with some preclinical evidence that fluvoxamine can improve 
PCP-induced cognitive deficits
Atomoxetine: norepinephrine selective reuptake inhibitor.
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Anticonvulsant Drugs 
Divalproex sodium: A fatty acid with anticonvulsant properties used in the treatment of 
epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by 
increasing gamma-aminobutyric acid levels in the brain. 
Riluzole: A glutamate antagonist (receptors, glutamate) used as an anticonvulsant 
(anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. 
Lamotrigine,Sodium Valproate, or Carbamazepine: Anticonvulsants 
Stimulant Drugs 
Methylphenidate is a racemic mixture comprised of the d- and l-threo enantiomers. The d-
threo enantiomer is more pharmacologically active than the l-threo enantiomer. 
Methylphenidate HCl is a central nervous system (CNS) stimulant.  
Methylphenidate transdermal system: Methylphenidate HCl is a central nervous system 
(CNS) stimulant.  
Choline and Cholinesterase Inhibitors 
Choline: Precursor to Acetylcholine 
Donepezil: Current theories on the pathogenesis attribute some symptoms to a deficiency 
of cholinergic neurotransmission. Donepezil hydrochloride is postulated to exert its 
therapeutic effect by inhibiting AChe boosting the availability of ACh.  
Drugs with Glutaminergic Effects, AMPA Modulators  and NMDA Antagonists  
Acamprosate is a derivative of the amino acid taurine and, like alcohol, reduces excitatory 
glutamate neurotransmission and enhances inhibitory GABA neurotransmission 
Memantine: a weak NMDA antagonist. Persistent activation of central nervous system N-
methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been 
hypothesized to contribute to the symptomatology of Alzheimer's disease.  
Dextromethorphan and quinidine sulfate (Nuedexta):  NMDA antagonist; Sigma 1 agonist; 
binds to SERT; proposed neuromodulator. 
Hormones 
Oxytocin: A nonapeptide hormone released from the neurohypophysis (pituitary gland, 
posterior). it differs from vasopressin by two amino acids at residues 3 and 8. 
Vasopressin 
Anti-infective-Anti-bacterial-Immunomodulators 
N Acetylcysteine N-acetyl derivative of cysteine. It is used as a mucolytic agent to reduce 
the viscosity of mucous secretions. It has also been shown to have antiviral effects in 
patients with HIV due to inhibition of viral stimulation by reactive oxygen. 
Cycloserine Antibiotic substance produced by Streptomyces garyphalus. 
Sapropterin: reduces blood phenylalanine (Phe) levels in patients with 
hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive 
Phenylketonuria (PKU). Proposed Neuroprotective and neurotransmitter effects. 
Mecobalamin: a study (PMID: 20406575 ) demonstrated a progressive decrease of sciatic 
nerve IGF-1 mRNA and peptide contents, and peripheral nerve dysfunction in the saline-
treated diabetics over 12 weeks in contrast to the normal control non-diabetics. 
Table 3. Sampling of Drugs in ASD Clinical Trials and Their Generally Proposed Actions 
www.intechopen.com
 Pharmacology  
 
292 
Study of Aripiprazole to Treat 
Children and Adolescents With 
Autism  
Phase II The Clinical Global impression (CGI) 
Improvement Scale.; The Irritability subscale of 
the Aberrant Behavior Checklist (ABC); The 
Clinical Global Impression Severity Scale. 
A Study of Aripiprazole in 
Children and Adolescents With 
Aspergers and Pervasive 
Developmental Disorder.  
Phase II The Clinical Global impression(CGI) 
Improvement Scale.; The Irritability subscale of 
the Aberrant Behavior Checklist (ABC); The 
Clinical Global Impression Severity Scale.;CY-
BOCS (Children's Yale-Brown Obsessive 
Compulsive Scale) 
Study of Aripiprazole in the 
Treatment of Serious Behavioral 
Problems in Children and 
Adolescents With Autistic 
Disorder (AD)  
Phase III Number of Participants With Serious Adverse 
Events (SAEs), Treatment-Emergent Adverse 
Events (AEs), Deaths, AEs Leading to 
Discontinuation, Extra Pyramidal  Syndrome 
(EPS)-Related AEs; Mean Change From 
Baseline in Total Simpson-Angus Scale (SAS)  
Aripiprazole in Children With 
Autism: A Pilot Study  
Phase II Clinical Global Impressions; Children's 
Psychiatric Rating Scale  
An Open-Label Trial of 
Aripiprazole in Autism 
Spectrum Disorders  
Phase II Clinical Global Impressions-Improvement; 
Aberrant Behavior Checklist-Irritability 
subscale  
Pilot Study of the Effect of 
Aripiprazole Treatment in 
Autism Spectrum Disorders on 
Functional Magnetic Resonance 
Imaging (fMRI) Activation 
Patterns and Symptoms  
Phase IV RBS-R (Repetitive Behavior Scale - Revised); 
CY-BOCS (Children's Yale-Brown Obsessive 
Compulsive Scale)  
OPT - Phase IV Long Term 
Maintenance Study of 
Aripiprazole for the Treatment 
of Irritability Associated With 
Autistic Disorder  
Phase IV Time from randomization to relapse; Mean 
change from end of Phase 1 to Week  16 
endpoint (LOCF) on the Aberrant Behavior 
Checklist - Irritability Subscale; Mean Clinical 
Global Impression - Improvement scale score 
at Week 16 endpoint (LOCF)  
Study of Aripiprazole in the 
Treatment of Children and 
Adolescents With Autistic 
Disorder (AD)  
Phase III Mean Change (Week 8 - Baseline) in the 
Autistic Behavior Checklist (ABC) Irritability  
Subscale Score; Mean Clinical Global 
Impressions Improvement Scale (CGI-I) Score;  
Number of Participants With Response at 
Week 8; Mean Change (Week 8 - Baseline)  
Study of Aripiprazole in the 
Treatment of Children and 
Adolescents With Autistic 
Disorder (AD)  
Phase III Mean Change (Week 8 - Baseline) in the 
Autistic Behavior Checklist (ABC) Irritability 
Subscale Score; Mean Clinical Global 
Impressions Improvement Scale (CGI-I) Score; 
Number of Participants With Response at 
Week 8; Mean Change (Week 8 - Baseline) 
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Evaluating the Effectiveness of 
Aripiprazole and D-Cycloserine 
to Treat Symptoms Associated 
With Autism  
Phase III Aberrant Behavior Checklist (ABC) Irritability 
Subscale; Clinical Global Impression (CGI) 
Scale; ABC Subscales; Vineland Maladaptive 
Behavior Subscales; A modified version of the 
Compulsion Subscale of the Children's Yale-
Brown Obsessive Compulsive Scale.  
Efficacy of Aripiprazole Versus 
Placebo in the Reduction of 
Aggressive and Aberrant 
Behavior in Autistic Children  
Phase I Clinical Global Impression Improvement (CGI-
AD); Aberrant Behavior Checklist;  Abnormal 
Involuntary Movement Scale (AIMS)  
Long-Term Olanzapine 
Treatment in Children With 
Autism  
Phase II 
Phase III 
Children's Psychiatric Rating Scale; Aberrant 
Behavior Checklist; Clinical Global 
Impressions; Treatment Emergent Symptoms 
Scale; Olanzapine Untoward Effects Checklist; 
Abnormal Involuntary Movement Scale; 
Neurological Rating Scale  
Table 4. Antipsychotic Clinical Trials, Trial Phase and Outcome Measures (Continued on 
table 5) 
 
A Controlled Study of 
Olanzapine in Children With 
Autism  
Phase II  Children's Psychiatric Rating Scale; Clinical 
Global Impressions; Abberant Behavior  
Checklist; Treatment Emergent Symptoms 
Scale; Olanzapine Untoward Effects Checklist; 
Abnormal Involuntary Movement Scale; 
Neurological Rating Scale  
Study of Paliperidone ER in 
Adolescents and Young Adults 
With Autism  
Phase III The IrritabIrritibility subscale of the Aberrant 
Behavior Checklist (ABC) will be used as the 
caregiver-rated primary outcome measure. The 
Clinical Global Impression- Improvement(CGI-
I) will be included as a primary outcome 
measure  
A Study of the Effectiveness and 
Safety of Two Doses of 
Risperidone in the Treatment of 
Children and Adolescents With 
Autistic Disorder  
Phase IV Allocation: Randomized; Endpoint 
Classification: Safety/Efficacy Study;  
Intervention Model: Parallel Assignment; 
Masking: Double Blind (Subject,  
Caregiver, Investigator); Primary Purpose: 
Treatment  
A Study of the Effectiveness and 
Safety of Risperidone Versus 
Placebo in the Treatment of 
Children With Autistic Disorder 
and Other Pervasive 
Developmental Disorders (PDD) 
Phase III Change in the Irritability Subscale of the 
Aberrant Behavior Checklist (ABC) and other 
ABC subscales at end of treatment compared 
with baseline; Change from  baseline to end of 
treatment in Nisonger Child Behavior Rating 
Form (N-CBRF),  Visual Analogue Scale 
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Pharmacogenomics in Autism 
Treatment  
Phase II 
Phase III 
ABC and CGI; ABC  
Treatment of Autism in Children 
and Adolescents  
Phase III  
Risperidone Pharmacokinetics in 
Children With Pervasive 
Developmental Disorder (PDD) 
Phase I  Quantify tVariability of clearance and volume 
of distribution among AE rating, weight gain 
and ABC responder status; Exploratory 
analysis will be performed to examine the 
relationship of other factors to risperidone and 
metabolite concentrations.  
Pharmacogenetics of 
Risperidone in Children With 
Pervasive Developmental 
Disorder (PDD)  
Phase I   
Comparison of Applied 
Behavioral Analysis (ABA) 
Versus ABA and Risperidone  
   
RUPP PI PDD: Drug and 
Behavioral Therapy for Children 
With Pervasive Developmental 
Disorders  
 Home Situations Questionnaire; Vineland 
Daily Living Skills Scale; Irritability subscale-
Aberrant Behavioral Checklist; Clinical Global 
Impressions-Improvement  
(CGI-I)  
Risperidone Treatment In 
Children With Autism Spectrum 
Disorder And High Levels Of 
Repetitive Behavior  
Phase II  Aberrant Behavior Checklist  
Ziprasidone in Children With 
Autism: A Pilot Study  
Phase II  Clinical Global Impressions; Children's 
Psychiatric Rating Scale  
An Observational Study to 
Evaluate the Safety and the 
Effects of Risperidone 
Compared With Other Atypical 
Antipsychotic Drugs on the 
Growth and Sexual Maturation 
in Children  
 To comparZ-scores for height, age at current 
Tanner stage, and prolactin-related  adverse 
events between patients exposed to 
risperidone and patients exposed to other 
atypical antipsychotic drugs.; Assess the 
prolactin value and risk of  hyperprolactine  
 
 
 
Table 5. Antipsychotic Clinical Trials, Trial Phase and Outcome Measures (Continued) 
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Citalopram for Children With 
Autism and Repetitive Behavior 
(STAART Study 1)  
Phase II Clinical Global Improvement; Safety 
Monitoring Uniform Research Form (SMURF); 
Children's Yale-Brown Obsessive-Compulsive 
Scale (CYBOCS); Repetitive Behavior Scale-
Revised (RBS-R); Parent Chief Complaint; 
Aberrant Behavior Checklist; 
Functional MRI Evaluation of 
the Effect of Citalopram in 
Autism Spectrum Disorders  
PhaseI Functional Magnetic Resonance Imaging; 
Clinicians Global Improvement Scale; 
Childrens Yale- Brown Obsessive Compulsive 
Scale 
Randomized Study of Fluoxetine 
in Children and Adolescents 
With Autism  
Phase I
Study of Fluoxetine in Adults 
With Autistic Disorder 
PhaseI
Extended Management and 
Measurement of Autism  
Phase III Safety Outcomes: Laboratory determinations, 
Urine drugs of abuse tests,Vital Signs,Physical 
Examinations, Adverse Events/Serious 
Adverse Events, Clinical Global Impression of 
Severity (CGI-S AD) 
Fluoxetine Essay in Children 
With Autism  
Phase II Subscores of Autism Diagnostic Interview 
(ADI-R)at each visit of the protocol 
(LECOUTER et RUTTER, 1989); Sides effect 
scale (FSEC); Aberrant Behavior Checklist 
(Aman et al., 1985); Clinical Global 
Impressions (CGI) severity and improvement. 
Study of Fluoxetine in Autism Phase III The percentage change from baseline to the 
endpoint visit for the CYBOCS-PDD score; The 
time and dose related course of therapeutic 
effects; The inter-relationship between these 
effects in the context of global clinical changes; 
The indirect effect.
Effectiveness of Early 
Intervention With Fluoxetine in 
Enhancing Developmental 
Processes in Children With 
Autism (STAART Study 2) 
Phase III Feasibility and safety of conducting placebo 
control trial of fluoxetine; Side effect and drop 
out evaluation  
Fluvoxamine and Sertraline in 
Childhood Autism - Does SSRI 
Therapy Improve Behaviour 
and/or Mood?  
Phase III The severity of the autistic child's behaviour or 
condition (assessed by parents); Weight and 
vital signs; Blood count and liver function 
studies 
Mirtazapine Treatment of 
Anxiety in Children and 
Adolescents With Pervasive 
Developmental Disorders 
Phase III Pediatric Anxiety Rating Scale (PARS); Clinical 
Global Impressions (CGI)  
Table 6. Antidepressant Clinical Trials, Trial Phase and Outcome Measures  
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Methylphenidate for Attention 
Deficit Hyperactivity Disorder 
and Autism in Children 
Phase III Conners' Teacher Rating Scale-Revised (CTRS-
R); Continuous Performance Test (CPT); 
Matching Familiar Figures Test (MFFT);  
Speeded Classification Task (SCT);   Delay of 
Gratification Task (DOG); Conners' Parent 
Rating Scale (CPRS)-Short Form;    
A Pilot Study of Daytrana TM in 
Children With Autism Co-
Morbid for Attention Deficit 
Hyperactivity Disorder (ADHD) 
Symptoms 
Phase III Determine if Daytrana is safe and well-
tolerated by children with Autism co-morbid 
for ADHD;   Determine if Daytrana is effective 
in both school and home  
 
 
Table 7. Stimulant Clinical Trials, Trial Phase and Outcome Measures  
 
 
Divalproex Sodium ER vs  
Placebo in 
Childhood/Adolescent Autism 
valproex Sodium vs. Placebo in 
Childhood/Adolescent Autism  
Phase II  Clinical Global Impression-Improvement;   
Aberrant Behavior Checklist Clinical Global 
Impression-Improvement;   Aberrant Behavior 
Checklist; Clinical Global Impression-
Improvement;   Aberrant Behavior Checklist  
Divalproex Sodium ER in Adult 
Autism 
Phase IV  
A Study of Divalproex Sodium 
in Children With ASD and 
Epileptiform EEG 
Phase II epileptiform EEG discharges;   Improvement in 
behavior 
Oxcarbazepine Versus Placebo 
in Childhood Autism 
1 Vineland Adaptive Behavior Scales;   Aberrant 
Behavior Checklist;   Clinical Global 
Impression Improvement Scale;   Autism 
Diagnostic Observation Schedule 
Riluzole to Treat Child and 
Adolescent Obsessive-
Compulsive Disorder With or 
Without Autism Spectrum 
Disorders 
Phase II Reduction of 30% or more in Children's Yale-
Brown Obsessive-Compulsive Scale (CY-
BOCS) and Repetitive Behavior Scale;   
Much/Very much improved on Clinical Global 
Impressions - Improvement score (CGI-I) 
Valproate Response in 
Aggressive Autistic Adolescents
Phase III  
 
 
Table 8. Anticonvulsant Clinical Trials, Trial Phase and Outcome Measures  
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Treatment With Acetyl-Choline 
Esterase Inhibitors in Children 
With Autism Spectrum 
Disorders 
Phase IV Core autistic symptoms (ATEC); Side effects 
and adverse events questionnaire; Linguistic 
performance (CELF-4); Adaptive functioning 
(Vineland-II); Co-morbid behaviors (CSI-4 
questionnaire); Executive functions (BRIEF) 
questionnaire 
Drug Treatment for Autism Phase II Cognitive Assessment 
The Effect of Donepezil on REM 
Sleep in Children With Autism 
Phase II The primary outcome measure of this protocol 
is to determine if donepezil can increase the 
percentage of time that subjects with autism 
spend in REM sleep.; A secondary aim of this 
protocol is to examine changes in functional 
outcome, including cognitive.  
Galantamine Versus Placebo in 
Childhood Autism 
Phase III Autism Diagnostic Observation Schedule-
Generic (ADOS-G)- Change from Baseline to 
Final Visit; Clinical Global Impression 
Improvement (CGI)- Change from Baseline to 
Final Visit; Aberrant Behavior Checklist (ABC) 
(hyperactivity/irritability sections). 
 
Table 9. AcetylCholine Esterase Inhibitors Clinical Trials, Trial Phase and Outcome 
Measures  
 
 
An Open Label Extension Study 
of STX209 in Subjects With 
Autism Spectrum Disorders 
Phase II Irritability subscale of the Aberrant Behavior 
Checklist 
Study of Arbaclofen for the 
Treatment of Social Withdrawal 
in Subjects With Autism 
Spectrum Disorders 
Phase II Aberrant Behavior Checklist-Social 
Withdrawal Subscale 
Open-Label Study of the Safety 
and Tolerability of STX209 in 
Subjects With Autism Spectrum 
Disorders 
Phase II Adverse events;   Irritability Subscale of the 
Aberrant Behavior Checklist, Community 
Version 
 
 
Table 10. Immunomodulator Clinical Trials, Trial Phase and Outcome Measures  
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Open-Label Extension Study of 
Kuvan for Autism 
Phase II 
Phase III 
Clinical Global Impressions Scale;   Vineland 
Adaptive Behavior Scale;   Clinical Global 
Impression: Severity;   Children's Yale Brown 
Obsessive Compulsive Scale;   Parental Global 
Assessment;   Preschool Language Scale;   
Connor's Preschool ADHD question 
Intranasal Oxytocin for the 
Treatment of Autism Spectrum 
Disorders 
Phase II Change from Baseline to week 12 on the 
Diagnostic Analysis of Nonverbal Accuracy 
(DANVA2);   Change from Baseline to week 12 
on the Social Responsivity Scale (SRS);   
Change from Baseline to week 12 on the 
Clinical Global Impressions Scale - 
Improvement 
Intranasal Oxytocin in the 
Treatment of Autism 
Phase II Clinical Global Impressions Scale (CGI);   
Diagnostic Analysis of Nonverbal Accuracy, 
Adult Paralanguage Test (DANVA2-AP);   
Repetitive Behavior Scale (RBS);   Event 
Contingent Reporting;   Yale-Brown Obsessive-
Compulsive Scale (YBOCS);   Social 
Responsiveness. 
An fMRI Study of the Effect of 
Intravenous Oxytocin vs. 
Placebo on Response Inhibition 
and Face Processing in Autism 
Phase I  
A Study of Oxytocin in Children 
and Adolescents With Autistic 
Disorder 
Phase II Tolerability of Oxytocin Nasal Spray;   
Biomarkers;   Feasibility;   Acceptability of 
Oxytocin Nasal Spray 
Brain Imaging Study of Adults 
With Autism Spectrum 
Disorders 
Phase I Changes in brain activations;   Performance 
scores and reaction time on behavioral tasks. 
Study of Glutathione, Vitamin C 
and Cysteine in Children With 
Autism and Severe Behavior 
Problems 
Phase I Improvement in both developmental skills and 
behavior with either glutathione or 
glutathione, Vitamin C and N-acetylcysteine 
therapy as compared to placebo therapy. 
Subjects will also be monitored using clinical 
and laboratory safety parameters. 
Synthetic Human Secretin in 
Children With Autism 
Phase III  
Synthetic Human Secretin in 
Children With Autism and 
Gastrointestinal Dysfunction 
Phase III  
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Sapropterin as a Treatment for 
Autistic Disorder 
Phase II Clinical Global Impression -- Improvement 
(CGI-I) Scale;   Preschool Language Scale 
(PLS);   Vineland Adaptive Behavior Scale-II;   
Children's Yale Brown Obsessive Compulsive 
Scale (C-YBOCS);   Connor's Preschool ADHD 
questionnaire;   Adverse Events Scale 
Secretin for the Treatment of 
Autism 
Phase III  
The Effects of Oxytocin on 
Complex Social Cognition in 
Autism Spectrum Disorders 
Phase I Empathic accuracy performance;   fmri BOLD 
response during empathic accuracy task 
Cholesterol in ASD: 
Characterization and Treatment 
Phase I 
Phase II 
Behavioral Changes 
Table 11. Hormone or Related Clinical Trials, Trial Phase and Outcome Measures  
A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour 
Problems in Children With ASD  
Atomoxetine and Parent Management Training in Treating Children With Autism and 
Symptoms of Attention Deficit Disorder With Hyperactivity  
Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents 
With Autism  
Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder 
(ADHD) in Children and Adolescents With Autism Spectrum Disorder  
Atomoxetine, Placebo and Parent Management Training in Autism  
Efficiency of Bumetanide in Autistic Children  
Early Pharmacotherapy Aimed at Neuroplasticity in Autism : Safety and Efficacy  
Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder  
A Trial of CM-AT in Children With Autism- Open Label Extension Study  
A Trial of CM-AT in Children With Autism  
Effects of CX516 on Functioning in Fragile X Syndrome and Autism  
Mercury Chelation to Treat Autism  
Dimercaptosuccinic Acid (DMSA) Treatment of Children With Autism and Heavy Metal 
Toxicity  
Trial of Low-Dose Naltrexone for Children With Pervasive Developmental Disorder (PDD)  
A Pilot Trial of Mecamylamine for the Treatment of Autism  
Treatment of Sleep Problems in Children With Autism Spectrum Disorder With Melatonin  
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An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic 
Medications.  
Efficacy Study of Subcutaneous Methyl-B12 in Children With Autism  
Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders  
Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum 
Disorders  
Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism  
Dose Finding Study of Pioglitazone in Children With Autism Spectrum Disorders (ASD)  
Transcranial Magnetic Stimulation (TMS) Measures of Plasticity and Excitatory/Inhibitory 
Ratio as Biomarkers: R-baclofen Effects in Normal Volunteers  
Melatonin for Sleep in Children With Autism  
Trichuris Suis Ova Adult Autism Symptom Domains  
Multidimensional Measurement of Psychopharmacological Treatment Response * CPI 
Table 12. Other Clinical Trials 
4. Pharmacological strategies in autism spectrum disorders 
Treatment monitoring and treatment response measurement provide methods by which 
treatment strategies may be assessed, tested and dynamically applied to the treatment 
process. Two examples are presented. The first illustrates the longitudinal measurement of 
risperidone response and the second illustrates a treatment review and re-conceptualization 
of treatment strategy. 
The first case is an actigraphic, psychometric and observational study of risperidone 
response in a six year old autism spectrum disordered child with Kabuki Syndrome. It 
provides an illustration of circadian and behavioral disturbances in a child, and the utility of 
single subject repeated actigraphic, psychometric and observational measurements of 
treatment response (Duke, 2010). 
Actigraphic measurements, such as those used in the following case, are not necessary to 
obtain meaningful treatment response data, although additional measurements, such as 
actigraphic data, are helpful.  
The non-invasive nature of watch-like actigraphy devices (Rispironics Actiwatch) is 
particularly attractive for use in pediatric populations. Meaningful treatment response 
measurements are obtained when actigraphic data is combined with psychometric and 
observational repeated measurements.  
This case study includes baseline and repeated psychological, observational and actigraphic 
measurements that were initiated prior to treatment with risperidone and repeated 
throughout the treatment process.  
Actigraphic measurements provide a basis by which to measure sleep and sleep onset 
latency as well as periods of mobility and immobility. In this case the actigraphic device was 
programmed to record activity every thirty seconds. 
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Actigraphic measurements were made utilizing a watch-like actigraphic device with an 11 
day baseline actigraphic measurement period and continued measurements that included 
the initiation of a pharmacological intervention for 6 days, followed by a planned 
adjustment to b.i.d. dosing that was measured for an additional 4 days. This initial 
actigraphic study resulted in over 65,000 measurements of activity. Repeated observations 
continued throughout the treatment period and actigraphic studies were repeated after 23 
months of risperidone treatment. 
The measurement methods included the Personality Inventory for Children (PIC) an 
objective multidimensional measurement of affect, behavior, ability and family function. 
The PIC was administered prior to treatment with risperidone and repeated after 23 months 
of treatment. The PIC serves as both an actuarial pre-treatment diagnostic tool as well as a 
post-treatment repeated measurement indicating treatment and developmentally associated 
change (Duke, B., 1991). 
Observational methods were employed throughout the treatment process. A primary 
observer (The Child’s Mother) was trained to report symptom percentages present since 
previous observations utilizing the operationally defined and observer defined items of the 
Systematic Observation Scale™ (Duke, B., 1990) throughout the treatment process. The 
Systematic Observation Scale™ utilizes single-subject repeated measurements. Symptoms 
and issues of interest are defined and a variety of frequency and sampling methods can be 
applied. The Systematic Observation Scale was designed so Primary Observers (parents, 
guardians, self observers or others) can make pre-treatment and subsequent observations to 
track, document and evaluate symptom variation over the course of an illness. The 
measurement utilized is the percentage of time the symptom is observed by the primary 
observer since the previous observation.  
 
Fig. 3. The child’s parents kindly consented to the use of this photograph. 
The actigraphic study was designed to select a child anticipating a psychopharmacological 
intervention. 
The study was reviewed and approved by the Child Psychopharmacology Institute 
Institutional Review Board and was registered with the National Institutes of Health 
Protocol Registration System (NCT00723580) as a non-randomized, single subject, case 
study clinical trial. 
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The Study Investigator's DSM-IV diagnoses were: 
- Axis I 
- 299.80 Pervasive Developmental Disorder Not Otherwise Specified  
- 314.01 Attention-Deficit Hyperactivity Disorder 
- 327.30 Circadian Rhythm Sleep Disorder (unspecified type) 
- Axis II 
- 317  Mild Mental Retardation 
- Axis III 
- Kabuki Syndrome* 
- Hearing Impairment 
The child’s impulsivity and inability to sleep represented a significant symptom and risk 
factors. She frequently moved about restlessly until 5:00 AM and would often sleep (or 
partially sleep) with her eyes open. She had frequent infections and had been previously 
stimulated by diphenylhydramine, over-sedated on clonidine and had mood destabilization 
when tried on mirtazapine. The child’s diagnosis of Kabuki Syndrome had been previously 
established by a geneticist at the Mayo Clinic. The child presented with severe impulsivity, 
psychomotor acceleration, severe insomnia and obsessive compulsive behaviors that 
included touching objects to the whites of her eyes (these behaviors occurred multiple times 
an hour). An MLL2 mutation has been verified in this child. It has recently been reported 
that Kabuki Syndrome is caused by mutations in MLL2, a gene that encodes a Trithorax-
group histone methyltransferase, a protein important in the epigenetic control of active 
chromatin states (Hannibal et, al, 2011). 
Dr. Niikawa and Dr. Kuroki described Kabuki Syndrome in 1981. The term was used 
because of the affected children’s facial resemblance to the famous Kabuki actors that 
perform in traditional Japanese theater. 
Kabuki Syndrome is rare and diagnosis is complicated by the diverse spectrum of 
characteristics. Arched eyebrows, thick eyelashes, eversion of the lateral lower lid and 
long palpebral fissures contribute to the resemblance. Skeletal and dermatological 
abnormalities are common along with short stature, behavioral and pervasive 
developmental disorders and mild to moderate intellectual disability. Congenital heart 
defects and hearing impairment are often associated with the syndrome. The proportion 
of male to female occurrence is equal and no correlation with birth order has been found 
(Adam & Hudgins, 2005). 
The assessment and treatment plan included a baseline biopsychosocial history, a baseline 
cognitive and personality assessment and the initiation of actigraphy measurements. The 
initial 21 day study of actigraphic measurements included an eleven day baseline prior to 
pharmacological interventions. The pharmacological Intervention following the medication 
free baseline utilized risperidone .25 mg q.h.s. initiated for seven days and then increased to 
twice daily dosing. Subsequent actigraphic measurements reflected the subsequent risperdal 
dose of .5 mg three times daily. Systematic observations continued throughout the treatment 
period and the personality assessment was repeated at the study end point. The established 
treatment goals were to: improve sleep; reduce general impairment; reduce hyperactivity; 
reduce impulsivity; reduce irritability and improve social functioning. 
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Hypotheses and Outcome Measures: 
H1: Reduced percentages of primary symptoms will be associated with increased sleep 
during sleep periods (activity and sleep measurements). Actiwatch Communication and 
Sleep Analysis Instruction Manual (Respironics). 
H2: Sleep quality will be reflected by reduced standard deviations of activity during sleep 
periods. 
H3: Positive treatment response as reflected by reduced percentages of primary symptoms 
will be associated with decreased activity during activity periods. 
H4: Reduced impulsivity will be associated with reduced standard deviations of activity 
during activity periods. 
Outcome Measures 
a. Actigraphic Measurement of Treatment Conditions: 
b. Baseline May 12, 2008 and two additional 21 day periods between May 12, 2008 to July 
14, 2010 
c. Systematic Observation ScaleTM Measurements: May 7, 2008 to July 14th, 2010 
d. Personality Inventory for Children-Revised: pre-test May 2008 and post-test April 2010 
 
 
 
 
 
 
 
Fig. 4. Target Symptoms by Treatment Condition (BL- .25 mg - .5 mg t.i.d) 
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Fig. 5. Personality Inventory Pre-Test and Post-Test 
Study conclusions: Sleep quantity was increased; Sleep quality was improved; Hyperactivity 
was reduced; Impulsivity was reduced; Significance between treatment conditions, activity 
and target symptoms was demonstrated. 
The second case is a ten year old male who had received numerous medications over the 
past several years. Despite these treatments, and optimal family environment and 
commitment, the primary symptoms of mood instability and cognitive impairment 
continued. The child was receiving aripiprazole 5 mg q.a.m. and Concerta 36 mg q.a.m. 
Prior to the treatment review, the child had become disinhibited and severely impulsive in 
response to treatment with an SSRI, which was discontinued. He had also demonstrated a 
dose related worsening when tried on quetiapine. The quetiapine was discontinued due to 
associated insomnia and worsened mood and behavioral states.  
At the time of the review the child presented with neurological immaturity, delayed fine 
motor integration, jerky saccadic eye movements and possible symptoms of partial complex 
seizures. The child's episodic emotional dyscontrol, attention and cognitive functioning did 
not appear to be, pharmacologically, optimally addressed.  
DSM IV Diagnoses: Axis I: 
299.80 Pervasive Developmental Disorder NOS  
296.90 Mood Disorder NOS 
314.01 Attention Deficit/Hyperactivity Disorder, Combined Type 
307.7 Encopresis 
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Sum of
Squares 
df 
Mean 
Square 
F Sig. 
Activity Between Groups 4.476E8 3 1.492E8 1057.569 .000 
Within Groups 2.698E10 191235 141065.613   
Total 2.742E10 191238   
Poor Sleep Between Groups 16583.631 4 4145.908 10.542 .002 
Within Groups 3539.583 9 393.287   
Total 20123.214 13   
Impulsive Between Groups 13278.274 4 3319.568 15.707 .000 
Within Groups 1902.083 9 211.343   
Total 15180.357 13   
Hyperactivit
y 
Between Groups 11034.524 4 2758.631 10.994 .002 
Within Groups 2258.333 9 250.926   
Total 13292.857 13   
Irritable Between Groups 838.095 4 209.524 4.481 .029 
Within Groups 420.833 9 46.759   
Total 1258.929 13   
Easily 
Distracted 
Between Groups 14721.131 4 3680.283 4.379 .031 
Within Groups 7564.583 9 840.509   
Total 22285.714 13   
 
Fig. 6. Treatment Response: Analysis of Variance 
Following the treatment review the initial strategy was to add carbamazepine 200 mg ER 
q.p.m. x 7 days then b.i.d. Subsequent to improved emotional stability and broadly 
reduced symptoms the contribution of aripiprazole was assessed by a dose reduction to 
2.5 mg q.a.m. for four days and subsequently replaced with risperidone .5 mg b.i.d.  
Plans were made to subsequently assess his stimulant treatment response as the 
monitoring continued. Figure 7 displays symptom percentage averages over the treatment 
transition. 
Printable observation forms and item defintions are available and free for  
non-commercial use on the Child Psychopharmacology Institute website (www. 
ChildPsychopharmacologyInstitute.org). 
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5. Pharmacological protection and prevention strategies on the horizon: 
Glutamatergic modulation and neuroprotection 
Although pharmacological interventions utilized in Autistic Spectrum Disorders are 
generally associated with targeting behavioral or emotional impairments, little attention has 
been given to the important potential of glutamatergic regulation and neuroprotection in 
this vulnerable population. 
While a single drug has not triumphed in the treatment of autism spectrum disorders, many 
drugs have proven helpful to varying degrees and for various purposes. The dearth of 
children’s pharmacological studies stand in stark contrast to wide use of pharmacological 
interventions in ASD children.  
 
 
 
 
 
 
Fig. 7. Symptom Percentage Observation Scale Averages  
Alternative pathways of ASD pathology being explored include the study of 
tetrahydrobiopterin (BH4) as a novel therapeutic intervention and point to ASD children as 
having low levels of BH4. Early studies suggest low BH4 levels during development have 
devastating consequences on the central nervous system leading to or potentiating the 
neuropathology of ASD (Frye, et al, 2010). These studies are promising and may suggest a 
role for BH4 treatment or treatment augmentation in the ASD population. 
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It is proposed that pharmacological approaches with neuroprotective characteristics have 
potential to reduce the dynamic pathogenic states that are likely occurring in highly 
symptomatic young children who are in developmentally critical stages of neural patterning 
and maturation. In a manner similar to the example provided regarding atypical 
antipsychotics, drugs will increasingly be chosen based on their particular characteristics or 
used together for separate or synergistic effects. 
Arriving at a full understanding of these approaches will take further studies that consider 
the potential for unwanted effects. The Frye study, for example, noted that based on seven 
studies in which 451 patients with autism were treated with sapropterin (synthetic BH4) that 
ninety-seven (21.5%) experienced adverse effects for which a causal relationship with the 
study drug could not be ruled out. The most frequently reported adverse effects were sleep 
disorders, excitement, hyperkinesia, enuresis and diarrhea. It will be important to learn if 
sapropterin’s benefits are primarily from developmentally critical neuroprotective effects 
and/or effects on neurotransmitters. It will also be important to determine if indiscriminate 
neurotransmitter potentiation in dysregulated neurons and circuits are being reflected in the 
adverse effect profile that some demonstrate. 
Synaptic molecules are important targets for protective treatments, to slow disease 
progression and preserve cognitive and functional abilities by preserving synaptic structure 
and function. Glutamate receptors and post synaptic density proteins play a central role in 
excitatory synaptic plasticity. Synaptic dysregulation may contribute to brain disorders 
present in those with Autism Spectrum Disorders by preventing appropriate synaptic 
signaling and plasticity. 
The NMDA receptor is fundamental to excitatory synaptic plasticity and neurological 
diseases. Synaptic loss is a pathologic correlate of cognitive decline. Synaptic dysfunction is 
evident long before synapses and neurons are lost. The synapse constitutes an important 
target for treatments to slow progression and preserve cognitive and functional abilities in 
these diseases. (van Spronsen & Hoogenraad,  2010 ) 
5.1 Excitotoxity and glutamatergic activity  
Current hypotheses propose excessive glutamate activity can lead to excitotoxicity 
interfering with normal neurodevelopment in schizophrenia. Similarly, these effects may be 
involved in the neurodevelopment in ASD. The excitotoxicity is hypothesized to continue 
and is linked to disease progression in schizophrenia ultimately resulting in pathologically 
functioning NMDA glutamate receptors. These hypotheses are consistent with those that 
identify the final common pathway of many neuropsychiatric diseases as synaptic 
pathology. 
While the future promises biomarkers, RNAi strategies, stem cell transplantation and other 
genetic treatments, arresting and/or reducing developmental pathogenic potential by 
discovering and developing methods of effecting glutamatergic regulation by NMDA 
antagonism or other methods is a worthy, if not urgent, treatment goal for Autism Spectrum 
Disordered children. Blocking or moderating excessive glutamate neurotransmission with 
NMDA antagonists may prevent or mitigate damage, maladaptive neurodevelopment or 
neurodegenerative processes.  
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Some NMDA antagonists appear to be neuromodulators that reduce the excitotoxicity 
effects of dysregulated circuits and support dendritic health, long term potentiation and 
neural plasticity. Such treatments may one day provide preventative pharmacological 
interventions as well as those that can reduce impairment and improve functioning.  
Two NMDA antagonists are particuilarly interesting candidates for therapeutic potential 
in the ASD population, memantine and dextromethorphan/quinidine (Duke & Kaye, 
2010).  
Memantine, as an augmenting agent, demonstrated significant improvements in open-label 
use for language function, social behavior, and self-stimulatory behaviors, although self-
stimulatory behaviors comparatively improved to a lesser degree. Chronic use so far 
appears to have no serious side effects (Chez MG, et al 2007).  
Dextromethorphan/quinidine (DM/Q) shares the attributes of being an uncompetitive 
NMDA antagonist with memantine, however, importantly; DM/Q is a sigma 1 agonist and 
binds to SERT. Binding data comparing memantine with DM/Q demonstrate the presence 
of Sigma 1 and SERT binding in DM/Q but not in memantine (Werling, et al 2007).  
One of the characteristics that suggests DM/Q might have therapeutic potential in ASD is 
its efficacy in pseudobulbar affect (PBA). The efficacy and safety of dextromethorphan and 
quinidine was demonstrated in clinical trials of late stage neurological conditions 
(amyotrophic lateral Sclerosis and Multiple Sclerosis) demonstrating reductions of 
emotional lability and improvements in sleep. These findings suggest that the 
pharmacological characteristics of DM/Q may, at some level rescue synaptic signaling and 
may have the potential to affect neurodevelopmental trajectory in dysregulated developing 
nervous systems such as those with Autism Spectrum Disorders. 
AVP-923 was approved by the FDA in 2010 as Nuedexta™ the first and only treatment for 
Pseudobulbar Affect (PBA). This is an important therapeutic for those suffering the 
debilitating effects of pseudobulbar affect. The efficacy in reducing dysregulated and 
involuntary congruent and incongruent emotional expressions is a significant achievement. 
Why is DM/Q (Nuedexta) effective in PBA?  That, of course, is unknown, but PBA is often 
considered the result of connectivity and neural circuitry failures and ASD is known to have 
signaling and connectivity pathologies. Emotional lability is often associated with 
behavioral dyscontrol, irritibility, assaultive and raging behaviors that prompt 
pharmacological intervention in children with ASD.  
NMDA antagonists may offer a therapeutic pathway through modulation or regulation of 
dysregulated glutamatergic processes. The potential of DM/Q (Nuedexta) in ASD, 
particularly in the early developmental stages of the illness, to rescue and support synaptic 
function is worthy of further study. 
Although the mechanism of action of DM/Q is not fully characterized, its unique properties 
as an NMDA receptor antagonist and as a Sigma 1 receptor agonist appear to convey effects 
of both neuroprotection and neuromodulation. Future studies will help us determine if 
these unique characteristics will lead to improved outcomes for those with autism spectrum 
disorders.  
www.intechopen.com
 Pharmacological Neuromodulation in Autism Spectrum Disorders 
 
309 
6. Conclusion 
The distress, irritability and emotional lability often seen in Autism Spectrum Disorders 
may be a reflection of pathological glutamatergic functioning or otherwise dysregulated 
circuits relative to inhibitory-excitatory balance. When sustained, these symptoms 
demonstrate potential for pathological development of abnormal neural circuits capable of 
dysregulation through neural synchronicity and state dependent effects on genetic 
expression. Within the framework of this hypothesis the neural plasticity and critical 
periods, present in developing brains, place them at particular risk.  
We currently have drugs and compounds that have the ability to reduce impairment and 
improve functioning in many with ASD when used, monitored and managed thoughtfully. 
Early pharmacological intervention related to severe emotional lability, irritability and 
dysregulated circuits may also reduce the pathogenic potential and reduce or prevent the 
development or maintenance of pathological processes.  
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